Blincyto 38.5 mcg for acute lymphoblastic leukemia

 Blincyto (blinatumomab) is a medication used to treat a specific type of blood cancer called Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

The dose of  Blincyto is based on the patient's weight and is given as a continuous intravenous infusion. The recommended starting dose for adults is 9 mcg/day, which is gradually increased over several days to a target dose of 28 mcg/day. The maximum dose is 42 mcg/day.

However, you mentioned 38.5 mcg," which is not a standard dosage for Blincyto. It's possible that you made a mistake in your question or that you have been prescribed a different dosage based on your individual circumstances.

In any case, it's important to follow your healthcare provider's instructions regarding the dose and administration of Blincyto or any other medication.

BLINCYTO TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

Blinatumomab (brand name Blincyto) is a medication used to treat a specific type of acute lymphoblastic leukemia (ALL) called Philadelphia chromosome-negative B-cell precursor ALL. Blinatumomab is a type of immunotherapy called a bispecific T-cell engager (BiTE) that works by connecting T-cells to cancer cells, which can help the immune system identify and destroy cancer cells.

Blinatumomab is given as an intravenous infusion over a period of four weeks, followed by a two-week break, and then another four-week infusion cycle. Treatment typically lasts for a total of six cycles. The medication is given in a hospital or infusion center, and patients are closely monitored for potential side effects.

Common side effects of Blinatumomab include fever, fatigue, headache, nausea, vomiting, diarrhea, and decreased appetite. More serious side effects can include infections, allergic reactions, neurological problems, and cytokine release syndrome, which is a potentially life-threatening immune response. Patients receiving Blinatumomab may also experience low levels of certain blood cells, which can increase the risk of bleeding or infections.

Blinatumomab can be a highly effective treatment for certain ALL types, but it is not suitable for everyone. It is important to discuss the potential risks and benefits of this medication with your doctor to determine if it is the right treatment for you.

ENHERTU: Adverse Drug Reactions

The most common side effects of Enhertu, including laboratory abnormalities, in patients with: metastatic breast cancer and HER2-mutant NSCLC were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, fatigue, decreased platelet count, increased aspartate aminotransferase, vomiting, increased alanine aminotransferase, alopecia, increased blood alkaline phosphatase, constipation, musculoskeletal pain, decreased appetite, hypokalemia, diarrhea, and respiratory infection.

  Gastric cancer was decreased hemoglobin, decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, nausea, fatigue, increased blood alkaline phosphatase, decreased appetite, increased aspartate aminotransferase, increased alanine aminotransferase, diarrhea, hypokalemia, vomiting, constipation, increased blood bilirubin, pyrexia, and alopecia.

Apart from these side effects, the drug is all set to use safely by an expert medical specialist. One can buy ENHERTU 100 mg injection online through various generic medication suppliers like Indian Pharma Network. Visit Contact us: Ikris Pharma Network | Toll-Free:- 1800 889 1064

ENHERTU: Storage and Availability 

The drug Trastuzumab deruxtecan, sold under the brand name Enhertu and is Stored in vials in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light until the time of reconstitution. It is made available online to buy. One can easily buy ENHERTU 100mg injection online or by contacting dealers who are recognized generic and innovative medication suppliers. 

Trodelvy Price for 180 MG Vial in India

Trodelvy is made of two different drugs joined together: a monoclonal antibody drug (which attaches to Trop -2 receptors, present on the outside of some cancer cells, and a chemotherapy drug (which stops all cells including unhealthy cells from growing and dividing). The monoclonal antibody drug attaches to the unhealthy cells and then releases the chemotherapy medicine directly into the cell.

Send your inquiry now to buy Trodelvy 180 mg vials online or know more about Trodelvy price (180 mg vial of sacituzumab govitecan) either via Call/WhatsApp: +919310090915, or TOLL-FREE: 1800-889-1064

The well-qualified and dedicated team at Indian Pharma Network provides a quick, predictable response to your quote requests immediately.

All pharmaceutical products – comparator drugs, adjunctive therapies, RLDs, co-meds, and rescue meds, and Exports/Imports drugs – are transported in standard temperature-controlled conditions with active monitoring in order to ensure the integrity of products. Contact us today to get/buy your hard-to-access prescription medicine at the lowest price from India.

TRIPLE-NEGATIVE BREAST CANCER AND THEIR TREATMENT

 Breast cancer is a major health concern for women around the world. While there are many types of breast cancer, one of the most concerning and difficult-to-treat kinds is known as triple-negative breast cancer (TNBC). TNBC often requires more aggressive treatments than other forms of breast cancer and can be especially difficult to diagnose. In this article, we’ll look at what TNBC is, its symptoms, and the treatment options available for those diagnosed with it.

What is triple-negative breast cancer?

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that does not express the hormone receptors for estrogen or progesterone and does not overproduce the HER2 protein. TNBC accounts for about 15 to 20 percent of all breast cancers. While this type of breast cancer is more aggressive and has a higher rate of recurrence than other types of breast cancer, there are still many effective treatment options available.

The most common treatment for TNBC is chemotherapy, which can be used to shrink the tumor and kill any remaining cancer cells. Other treatment options include targeted therapy, radiation therapy, and surgery. Some women with TNBC may also receive hormone therapy or immunotherapy.

It is important to talk to your doctor about all of your treatment options and make a decision that is right for you. With advances in treatments, many women with TNBC are able to live long and healthy lives after their diagnosis.

Who is at risk for developing triple-negative breast cancer?

There are several risk factors for developing triple-negative breast cancer, including:

•  Personal history of breast cancer
•  Family history of breast cancer (especially in a first-degree relative)
•  Previous radiation therapy to the chest area
•  Inherited genetic mutations, such as BRCA1 or BRCA2 mutations
•  African-American or Hispanic ethnicity
• Being premenopausal or perimenopausal

If you have any of these risk factors, it’s important to talk to your doctor about your risks and what you can do to reduce them.

How is triple-negative breast cancer diagnosed?

There are a few different ways that triple-negative breast cancer can be diagnosed. A common way is through a mammogram, which is an X-ray of the breast. Other ways include a breast MRI, a breast ultrasound, or a biopsy.

A biopsy is when a small sample of tissue is taken from the breast and looked at under a microscope. This is the only way to definitively diagnose triple-negative breast cancer. There are two types of biopsies: needle biopsies and surgical biopsies. In a needle biopsy, a thin needle is inserted into the breast to remove cells or fluid. In a surgical biopsy, part of the tumor is removed surgically.

Triple-negative breast cancer can also be staging using imaging tests such as CT scans, PET scans, and bone scans. These tests help determine if the cancer has spread beyond the breast and to what extent.

Are there any clinical trials currently testing new treatments for triple-negative breast cancer?

There are a number of clinical trials currently underway testing new treatments for triple-negative breast cancer. These include trials testing new targeted therapies, immunotherapies, and combination therapies. Some of these trials are specifically for women with triple-negative breast cancer who have previously been treated with chemotherapy, while others are open to all women with this type of breast cancer. Clinical trials offer patients the opportunity to receive cutting-edge treatment that is not yet available to the public. If you are interested in enrolling in a clinical trial, speak to your doctor about your options.

What can I do to reduce my risk of developing triple-negative breast cancer?

There are a few things you can do to reduce your risk of developing triple-negative breast cancer:

• Maintain a healthy weight and body mass index.
• Get regular exercise.
• Limit your alcohol intake.
• Avoid smoking.
• Limit your exposure to environmental pollutants and toxins.
• Eat a healthy diet rich in fruits, vegetables, and whole grains.
• Consider taking a daily multivitamin or supplementing with folic acid, vitamin D, and calcium.
• Get regular screenings and mammograms, especially if you have a family history of breast cancer or are over the age of 40.

Trodelvy Injection price in India

 Trodelvy: Injection for intravenous infusion

The FDA approved medicine Trodelvy contains Sacituzumab govitecan-hziy that is used to treat patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This medicine is supplied in 180 mg lyophilized powder in single-dose vials to administer intravenously. The active ingredient in the vials is Sacituzumab govitecan-hziy with inactive ingredients  2-(N-morpholino) ethane sulfonic acid (MES), polysorbate 80 and trehalose dihydrate. One should not substitute Trodelvy for or use with other drugs containing irinotecan or its active metabolite SN-38.  

One can readily purchase Trodelvy 180 mg injection readily from certified generic medicine suppliers in India. Indian Pharma Network is one of the WHO-GDP certified pharmaceutical suppliers, supplying quality medicines for more than 8 years

Trodelvy: Dosage and Schedule

The medicine Trodelvy contains Sacituzumab govitecan-hziy is used to treat patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Trodelvy comes in the form of single-use vials in 180 mg to administer intravenously. The recommended dose of Trodelvy is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. One should continue treatment until disease progression or unacceptable toxicity and should not administer Trodelvy injection at doses greater than 10 mg/kg.   

One should administer Trodelvy as an intravenous infusion only and should not administer as an intravenous push or bolus. In the first infusion one should administer infusion over 3 hours. Observe patients during the infusion and for at least 30 minutes following the initial dose, for signs or symptoms of infusion-related reactions. In case of subsequent infusions one should administer infusion over 1 to 2 hours if prior infusions were tolerated and observe patients during the infusion and for at least 30 minutes after infusion. 

Healthcare professionals recommend prior to each dose of Sacituzumab govitecan 180 mg, premedication for prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting (CINV).  

Trodelvy : Suppliers in India 

The medicine Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of  Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) and Locally advanced or metastatic urothelial cancer (mUC). This medicine comes in single-dose vials in 180 mg for intravenous infusion. 

There are several certified suppliers of Trodelvy in India, and one can buy this medicine at a reasonable price. If you want to know more, call us at 18008891064.

Enhertu: Know about Medication

 Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of: 

adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received two or more anti-HER2-based regimens in the metastatic setting. 

adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have previously received a trastuzumab-based regimen.

Recommended Dosage: The recommended dosage of  Enhertu 100 mg Injection for Metastatic Breast Cancer and Locally Advanced or Metastatic Gastric Cancer is 5.4 mg/kg and 6.4 mg/kg respectively, administered as an intravenous infusion once every three weeks (21-day cycle) until the disease is progressive or unacceptable toxicity occurs. 

In case a planned dose is missed or delayed, administer as promptly as possible; avoid waiting until the next planned cycle. Adjust the schedule of administration in order to maintain a 3 week interval between doses. The infusion is administered at the dose and rate the patient tolerated in the most recent infusion.

Serious, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, may occur in patients treated with trastuzumab deruxtecan injection. Monitor patients for signs/symptoms of ILD. Promptly assess evidence of ILD. Evaluate patients with suspected interstitial lung disease by radiographic imaging. 

Serious neutropenia, including febrile neutropenia, may occur in patients treated with Trastuzumab Deruxtecan. Monitor complete blood counts before initiating treatment and before each dose. On behalf of the severity of neutropenia, this medicine may require dose interruption or reduction. 

Patients treated with enhertu injection may be at higher risk of having left ventricular dysfunction. LVEF needs to be assessed before initiating treatment and at regular intervals throughout the treatment. LVEF decrease needs to be managed through therapy interruption. 

Depending on its mechanism of action, enhertu can cause fetal harm if used by a pregnant woman. Pregnancy status needs to be verified prior to the initiation of treatment with this drug. Women should not breastfeed while on treatment and for 7 months after the final dose of Enhertu. 

Documentation & Availability:

What documents are required to import ENHERTU to India?

ENHERTU (fam-trastuzumab deruxtecan-nxki) can be imported by patients or GOVT hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients id proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is ENHERTU available in India?

ENHERTU (trastuzumab deruxtecan injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

On availability of enhertu in India (Ahmedabad, Mumbai, Kolkata, Hyderabad, Chennai, Delhi, Bangalore and Pune etc.)

• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

ENHERTU can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of ENHERTU (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for price of enhertu 100 mg injection price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Sourcing & Delivery:

Indian Pharma Network is able to source the ENHERTU (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

FAQs:

What is the Generic Name for the trade name drug Enhertu®?

Fam-trastuzumab Deruxtecan-nxki is Generic Name for the trade name drug Enhertu®.

Is Enhertu® approved by the FDA?

Yes, Enhertu® is approved by the FDA. Date of approval: May 4, 2022.

What is the dosage and form of Enhertu® supplied?

Enhertu® is supplied for injection: 100 mg lyophilized powder in a single-dose vial for intravenous administration. 

Does Enhertu® cause hair loss?

Yes, hair loss is the most common adverse reaction of Enhertu®. 

Is Enhertu® chemotherapy or immunotherapy?

Enhertu® is a chemotherapy and it is also a targeted therapy anti-cancer medicine. 

What are the most common side effects due to Enhertu®? 

Most common side effects due to Enhertu® in patients with breast cancer were nausea, WBC count decreased, fatigue, vomiting, alopecia, platelet count decreased, constipation, decreased appetite, anemia, hypokalemia, diarrhea, and cough.

Most common side effects in patients with gastric cancer were nausea, decreased appetite, anemia, fatigue, blood alkaline phosphatase increased, alanine aminotransferase 

increased, hypokalemia, diarrhea, vomiting, constipation, pyrexia, blood bilirubin increased, and alopecia. 

How much does Enhertu® cost in India?

The enhertu cost in India is reasonable. To procure this breast and stomach cancer medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Enhertu®?

Store vials of Enhertu in a refrigerator at 2-8°C (36-46°F) in the original carton in order to protect from light until time of reconstitution. Avoid freezing. Avoid shaking the reconstituted or diluted solution. 

What are the Highlights of prescribing information for Enhertu®?

Click Here to download full Enhertu prescribing information.

Source - https://bit.ly/3orFBpk

Enhertu an Anti – Cancer Drug

What is Enhertu ?

Enhertu (Fam-trastuzumab deruxtecan-nxki) is used in chemotherapy as a chemo drug and also for Anti – Cancer targeted therapy as an anti cancer drug . 

Enhertu side effects: The most commonly reported side effects of Enhertu are:

• cough
• nausea
• vomiting
• fatigue
• hair loss
• constipation
• anemia
• diarrhea
• decreased appetite
• low white blood cell counts

This medicine also can cause some serious side effects. While these serious effects are less common, it’s crucial to know about them:

Heart problems: Enhertu may be responsible for causing serious heart complications, including a few that don’t have signs/symptoms, such as reduced heart function, and a few that do have signs/symptoms, such as congestive heart failure. Signs/symptoms to monitor for include shortness of breath, swelling of the ankles or legs, cough, or weight gain of more than five pounds in less than 24 hours.

Interstitial lung disease: Interstitial lung disease (ILD) is a general term for such disorders that are responsible for causing inflammation and scarring in the lungs. The scarring makes lung tissue stiff, which makes it tough to breathe. Patients should be precisely monitored for signs of ILD while on treatment with Enhertu and inform your health specialist right away in case you have a dry cough or experience shortness of breath. 

How Enhertu helps in fighting Cancer?

Trastuzumab the antibody part targets and gets attached to the Her2 receptor of the cancer cells . Once the Trastuzumab is attached the chemotherapy part 

(deruxtecan) gets released in the cancer cells and destroys the cancer cells and other surrounding cancer cells . 

What are the ingredients in Enhertu? 

fam-trastuzumab deruxtecan-nxki is the active ingredient in Enhertu and inactive ingredient includes L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose. 

Can you Explain the Trastuzumab and Deruxtecan section of Enhertu in a better way ? 

Yes , Enhertu has been made in combination of 2 different cancer drugs that are Trastuzumab section which is a targeted therapy and designed for find and target the Her2 receptor on cancer cells and Deruxtecan section which destroys the cancer cells after it has been targeted . So it is made by two drugs by joining two different ADC ( Antibody -drug conjugate ) . 

Is enhertu for breast cancer

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer. Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer.

What is dosage form and strength of Enhertu ? Please also tell how it can be taken . 

Enhertu is supplied as an injection of 100 mg lyophilized powder in a single-dose vial , normally given as an IV (intravenous) infusion once enery 3 weeks , still we would suggest to ask a authorised doctor before taking a specific dose of Enhertu , and please don’t take this medicine without the advice of an authenticated doctor .  

What to expect when taking Enhertu? 

Enhertu (Fam-trastuzumab deruxtecan-nxki) is given intravenously, which means this medication is typically delivered directly into the bloodstream through an IV or port. Medicine is prescribed every 3 weeks unless the disease grows or unacceptable adverse reactions develop.

Those who are pregnant or want to get pregnant should not use Enhertu. This medicinal product can be responsible for causing embryo death and birth defects. It’s necessary that women don’t get pregnant while on treatment with Enhertu; effective birth control should be considered. 

Is there hair loss with the patients of Enhertu ?

Yes , hair loss is a common side effect faced by the patients of Enhertu 

own country ? 

Yes Indian pharma network  Named Patient program help’s patient to procure the medicines which are not available or approved in one’s own country . Indian pharma network  provides access to Enhertu (Fam-trastuzumab deruxtecan-nxki) Manufactured by: Daiichi Sankyo, Inc., and Marketed by AstraZeneca Pharmaceuticals LP, Wilmington . 

More - Enhertu: Know about Medication